

Summary of NICE Guidelines

Title	Coeliac disease: recognition, assessment and management
NICE Reference	NG20
Date of Review:	October 2017
Date of Publication	September 2015 (reviewed February 2016)
Summary of Guidance (Max 250 words)	Coeliac disease is an autoimmune condition associated with chronic inflammation of the small intestine. It is suggested that in the UK 1 in 100 people are affected.
	 Offer serological testing for coeliac disease to: People with any of the following: persistent and unexplained abdominal/gastrointestinal symptoms, faltering growth, prolonged fatigue, unexpected weight loss, severe/persistent mouth ulcers, unexplained iron, vitamin B12 or folate deficiency, type 1 diabetes, autoimmune thyroid disease, irritable bowel syndrome. First-degree relatives of people with coeliac disease.
	Investigations are to be carried out when following a gluten containing diet. Serological tests for suspected coeliac disease in children, young people and adults include: - Total immunoglobulin A (IgA) and IgA tissue transglutaminase (tTG). - IgA endomysial antibodies (EMA) if IgA tTG is weakly positive. - Consider IgG EMA, IgG deaminated gliadin peptide (DGP) or IgG tTG if IgA is deficient (total IgA <0.07g / litre).
	Do not use human leukocyte antigen (HLA) DQ2 (DQ2.2 and DQ 2.5)/DQ8 in the initial diagnosis in non-specialist settings. Consider testing in specialist setting for example, in children not having a biopsy.
	Referral: - Young people and adults with a positive serological test should be referred to a gastrointestinal specialist for endoscopic intestinal biopsy to confirm or exclude coeliac disease, and children to a paediatric gastroenterologist. - Refer people with negative serological tests if coeliac disease is still clinically suspected. Treatment: - Lifelong gluten free diet. Monitoring: - Review weight, height, symptoms & adherence to diet. Consider referring for an endoscopic intestinal biopsy if exposure to gluten has been excluded but serological titres are still high, change little over 12 months, or symptoms persist.

Impact on Lab (See below)	☐ Moderate
Lab professionals to be made aware	✓ Clinical Scientist ✓ Biomedical Scientist
Please detail the impact of this guideline (Max 150 words)	Clinical scientists and laboratory staff should be aware of the different immunoglobulin tests, and when they are appropriate to use. This should include clear reporting structures for clinicians. There are a broad range of symptoms associated with coeliac disease, leading it to be a high demand test. The guidelines state that healthcare professional should have a low threshold for re-testing individuals, particularly first degree relatives and people with type 1 diabetes, if they develop symptoms consistent with coeliac disease.

Impact on Lab

- None: This NICE guideline has no impact on the provision of laboratory services
- Moderate: This NICE guideline has information that is of relevance to our pathology service and may require review of our current service provision.
- **Important:** This NICE guideline is of direct relevance to our pathology service and will have a direct impact on one or more of the services that we currently offer.

Written by: Dr Alexandra Hughes Reviewed by: Dr Andrew Whyte